DR. MUHARREM GOKCEN, MD
Osteopathic Medicine at Duluth St, Minneapolis, MN

6428785, Aug 6, 2002

Oct 28, 1999

09/428375

Muharrem Gokcen - Minneapolis MN

Immunolytics Inc. - Minneapolis MN

A61K 3854

424 942, 424 946, 424 9462, 424 9466, 424 9467, 436 64

A method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase. In one embodiment, a method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase and at least one of a glycosidase, a protease, a nuclease, a lipase, an esterase, a plasminogen activator, a streptokinase, and combinations thereof. Preferably a glycosidase, such as, for example, hyaluronidase, is administered. Compositions used in methods for treating prostate cancer can also include or be administered with calcium ions, a nonionic surfactant, such as, for example, Triton® X-100, and an antibiotic, such as, for example, gentamicin. Another method of treating prostate cancer in a living mammal includes activating PSA in vivo by, for example, locally administering calcium ions.

6913744, Jul 5, 2005

Jan 22, 2002

10/055063

Muharrem Gokcen - Minneapolis MN, US

Immunolytics Inc. - Minneapolis MN

A61K038/43, A61K038/54, A61K038/46

424 941, 424 942, 424 9462, 424 9467

A method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase. In one embodiment, a method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase and at least one of a glycosidase, a protease, a nuclease, a lipase, an esterase, a plasminogen activator, a streptokinase, and combinations thereof. Preferably a glycosidase, such as, for example, hyaluronidase, is administered. Compositions used in methods for treating prostate cancer can also include or be administered with calcium ions, a nonionic surfactant, such as, for example, Triton® X-100, and an antibiotic, such as, for example, gentamicin. Another method of treating prostate cancer in a living mammal includes activating PSA in vivo by, for example, locally administering calcium ions.

6296847, Oct 2, 2001

Nov 17, 1993

8/154158

Muharrem Gokcen - Minneapolis MN
Terry J. Guy - Chaska MN

Immunolytics, Inc. - Minneapolis MN

A61K 3854

424 942

The invention provides a composition and method for treating benign prostatic hypertrophy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.

5116615, May 26, 1992

May 30, 1991

7/707628

Muharrem Gokcen - Minneapolis MN
Terry J. Guy - Chaska MN

Immunolytics, Inc. - Minneapolis MN

A61K 3762, A61K 37547, A61K 3754, A61K

424 942

The invention provides a composition and method for treating benign prostatic hypertropy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.